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Abstract 
Nitric oxide (NO) production is diminished in many patients with 
cardiovascular and renal disease. Asymmetric dimethylarginine (ADMA) is an 
endogenous inhibitor of NO synthesis, and elevated plasma levels of ADMA 
are associated with poor outcomes. Dimethylarginine 
dimethylaminohydrolase-1 (DDAH1) is a methylarginine-metabolizing enzyme 
that reduces ADMA levels. We reported previously that a DDAH1 gene variant 
associated with increased renal DDAH1 mRNA transcription and lower 
plasma ADMA levels, but counter-intuitively, a steeper rate of renal function 
decline. Here, we test the hypothesis that reduced renal-specific ADMA 
metabolism protects against progressive renal damage. 
Renal DDAH1 is expressed predominately within the proximal tubule. A 
novel proximal tubule-specific Ddah1 knockout (Ddah1PT-/-) mouse 
demonstrated tubular cell accumulation of ADMA and lower NO 
concentrations, but unaltered plasma ADMA concentrations. Ddah1PT-/- mice 
were protected from reduced kidney tissue mass, collagen deposition, and 
profibrotic cytokine expression in two independent renal injury models, folate 
nephropathy and unilateral ureteric obstruction. Furthermore, a study of two 
independent kidney transplant cohorts revealed higher levels of human renal 
allograft methylarginine-metabolizing enzyme  gene expression associating 
with steeper function decline. Additionally, we report an association between 
DDAH1 expression, NO activity, and uromodulin expression supported by 
data from both animal and human studies, raising the possibility that kidney 
DDAH1 expression exacerbates renal injury through uromodulin-related 
mechanisms.  
Together, these data demonstrate that reduced renal tubular ADMA 
metabolism protects against progressive kidney function decline. Thus, 
circulating ADMA may be an imprecise marker of renal methylarginine 
metabolism and therapeutic ADMA reduction may even be deleterious to 
kidney function.  
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Introduction 
Chronic kidney disease (CKD) poses an increasing global disease burden and 
contributes to cardiovascular disease (CVD), which is the leading cause of 
death worldwide. 1,2 CKD is associated with reduced bioavailability of nitric 
oxide (NO), which is required to maintain normal vascular and kidney function. 
3,4 Asymmetric dimethylarginine (ADMA) is released into the cytoplasm during 
normal protein turnover and competes with L-arginine binding at the active 
site of nitric oxide synthase (NOS) to block NO synthesis. The methylarginine-
metabolising enzymes (MAMEs); dimethylarginine dimethylaminohydrolase 
isoforms 1 and 2 (DDAH 1 and 2) and alanine-glyoxylate aminotransferase-2 
(AGXT2), 5 metabolize ADMA and other methylarginines to inactive products. 
Thus, MAMEs represent alternative pathways of endogenous NO regulation. 6 
The kidney expresses all MAME and NOS isoforms in a cell-specific 
distribution 5,7,8 thereby providing the means for intricate, cell type-specific 
control of NO bioavailability. Renal NO regulates hemodynamics, 9 afferent 
arteriolar vascular reactivity, 10 glomerular filtration, 11 tubular reabsorption 
and solute excretion. 8,12 Specifically, the proximal tubule (PT) is the principal 
renal cell type expressing the enzyme with the greatest activity for metabolism 
of ADMA, DDAH1, 7,13 although how this influences tubular reabsorption and 
response to injury through NO-ADMA regulation is unclear. Human studies 
demonstrate arterio-venous ADMA gradients across the kidney, which 
represent a large proportion of total body ADMA clearance through enzymatic 
metabolism and urinary excretion. 14 Consequently, plasma ADMA levels rise 
with declining kidney function, as demonstrated by Vallance et al with an early 
report of elevated plasma ADMA, lower NO and vascular dysfunction in 
patients with end-stage renal disease (ESRD). 15 
Raised circulating ADMA is a powerful predictor of progressive CVD 
and CKD, independent of eGFR and other traditional risk factors. 16-20 Since 
plasma ADMA increases with declining kidney function, the direction of 
causality is difficult to resolve by correlation alone. Although increased plasma 
ADMA levels may correlate with reduced total body NO bioavailability, they do 
not necessarily reflect the balance of NOS inhibition within the renal 
interstitium during progressive CKD. Our published data suggests that lower 
plasma ADMA does not necessarily protect against renal function decline and 
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that increased DDAH1 activity limited to the kidney may in fact be harmful. 
Thus, we reported a non-coding DDAH1 variant (rs17384213) that was 
associated with higher renal DDAH1 mRNA expression and lower plasma 
ADMA concentrations but counter-intuitively, this correlated with a faster rate 
of eGFR decline in two independent cohorts of patients with CKD. 21 It is 
possible that competitive inhibition of NOS by ADMA plays both protective 
and pathogenic roles, 6 determined by factors such as disease site, time-
course and magnitude of response.  
In light of these uncertainties, it is clearly important to define the role of 
PT-specific DDAH1 in CKD progression. We hypothesised that reduced renal 
DDAH1 activity protects against renal function decline, independent of 
circulating NO and ADMA.  
 
Results 
Proximal tubule (PT) specific gene targeting 
 The proximal tubule (PT) is the principal renal cell type to express 
DDAH1 (7,13 and Figure 1). Conditional proximal-tubule specific gene 
manipulation was achieved using the KAP2iCre gene construct. 22 Regulatory 
elements of the KAP (kidney androgen-regulated protein) promoter and 
angiotensinogen genes confer highly PT-specific, codon-optimised Cre (iCre) 
expression in response to androgen stimulation. 
Two double transgenic mouse strains were created, both possessing 
the KAP2iCre gene along with either; ROSA26eYFP – a reporter strain 
designed to confirm PT-specific gene manipulation (loxP sites flank a YFP 
STOP codon; Figure 2A), or floxed Ddah1 (loxP sites flank exon 1 of Ddah1 
which encodes the initiating methionine residue and the first 100 amino acids 
of the protein; Figure 2D). 23 In order to achieve temporal control over PT-
specific KAP2iCre expression and gene disruption, only female mice were 
treated with exogenous testosterone and used for study. 
YFP expression in female KAP2iCre/ROSA26eYFP reporter mice 
treated with testosterone was demonstrated using ImageStream analysis of 
isolated renal tubular cells (Figure 2B) and by renal tissue histology (Figure 
2C). Mice not possessing the KAP2iCre transgene did not express YFP. 
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PT-specific Ddah1 deletion 
The Ddah1 gene was deleted after testosterone exposure in 
KAP2iCre/Ddah1-floxed mice (Ddah1PT-/-) but not in Ddah1-floxed (Ddah1fl/fl) 
controls (Figure 2E). Reduced Ddah1 expression was clearly observed in the 
kidney where it exceeded 50% (Figure 2F; p<0.05). Non-significant reductions 
were detected in the liver and brain. Whole kidney lysate DDAH1 protein 
expression in Ddah1PT-/- mice was reduced by ~80% (Figure 2G; p<0.001) 
and enzymatic DDAH1 activity was reduced by ~70% (Figure 2H; p<0.05). 
 
Downstream effects of PT-specific Ddah1 deletion on MAs and NO 
ADMA recovered from isolated renal tubules was almost 7-fold higher 
(p<0.05) and NOx was 2.5-fold lower (p<0.05) in Ddah1PT-/- mice versus 
Ddah1fl/fl controls (Figure 3A, B). The impact of PT-specific Ddah1 deletion 
was restricted to tubular isolates and not evident in whole kidney tissue, 
plasma or urine, indicating tubule-specific ADMA-NO perturbation (Figure 3A-
H). This was further demonstrated by an absence of baseline effects upon 
renal expression of alternative MAME isoforms and NOS enzymes (Figure 3I); 
systolic BP (Figure 3J); renal function according to plasma creatinine (Figure 
3K) and urinary volumes (Figure 3L). 
 
Effects of PT-specific Ddah1 deletion on urine biochemistry 
Urinary electrolytes, protein and amino acid concentrations were not 
significantly affected by PT-specific Ddah1 deletion (Figure 4A-F). However, 
using a proteomic approach, significant effects of tubular Ddah1 disruption 
upon a number of urinary peptides were observed under baseline conditions. 
Of 1057 peptides screened in Ddah1PT-/- and Ddah1fl-/fl mouse urine, relative 
concentrations of 82 peptides were significantly altered (Figure 5; p<0.05). 
Most significantly downregulated in Ddah1PT-/- mouse urine was uromodulin 
(UMOD), (8.5-fold lower in urine from Ddah1PT-/- mice compared to Ddah1fl-/fl 
controls) (Figure 5; p=0.00042 or q=0.00083). In addition, urinary Col1α1 was 
down-regulated 6.5-fold in Ddah1PT-/- mice (p=0.0013; q=0.0017) at baseline.  
 
The effect of PT-specific Ddah1 deletion in folate nephropathy  
A single intra-peritoneal injection of folate induced an acute tubular injury in all 
mice, manifested by gross tubular dilatation, luminal casts and interstitial 
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inflammatory cell infiltrates (Figure 6; see Supplementary Material for a full 
characterization of folate nephropathy in wild-type mice). At 12 weeks 
following folate, significant differences emerged between Ddah1PT-/- and 
Ddah1fl-/fl control mice. Renal collagen deposition was significantly lower in 
Ddah1PT-/- mice treated with folate compared to Ddah1fl-/fl controls (Figures 7 
and 8; p<0.05). In addition, reduction in renal mass according to kidney:body 
weight ratios was significantly attenuated in Ddah1PT-/- versus Ddah1fl-/fl mice 
(Figure 7B; <0.01). Kidney tissue pro-fibrotic cytokine expression was 3 - 5 
fold lower in Ddah1PT-/- mice (Figure 7C; Col1a2 p<0.05; TGFβ <0.01; ET-1 
p<0.05). Furthermore at 12 weeks, Ddah1PT-/- mice were protected from other 
manifestations of advanced renal impairment such as hypertension (systolic 
BP; Figure 7D; p<0.01) and raised plasma creatinine (Figure 7E; p<0.001). 
There was a trend toward lower levels of proteinuria in Ddah1PT-/- mice 
although this did not reach statistical significance (Figure 7E; p=0.21).  
 
The effect of PT-specific Ddah1 deletion in unilateral ureteric obstructive 
(UUO) nephropathy  
In order to confirm that the protection against fibrosis observed with PT-
specific Ddah1 deletion was not a phenomenon unique to folate toxicity, 
Ddah1PT-/- mice were exposed to a second renal injury model; unilateral 
ureteric obstruction (UUO). (See Supplementary Material for a detailed 
characterization of UUO nephropathy in wild-type mice). 
At two weeks following UUO, severe tubulointerstitial disease was 
evident in kidney sections from obstructed kidneys, with gross tubular 
dilatation, epithelial cell flattening, parenchymal thinning and collagen 
deposition (Supplementary Material).  When compared to Ddah1fl/fl controls, 
kidney tissue from Ddah1PT-/- mice exhibited reduced loss of renal mass 
(p<0.05) and collagen deposition (p<0.05; Figure 9A-C). Furthermore kidney 
tissue expression of pro-fibrotic genes Col1α2 and TGFβ was significantly 
lower in Ddah1PT-/- mice (p<0.05; Figure 9D). 
Allograft MAME expression and eGFR decline in humans 
To confirm laboratory findings described above, we measured kidney tissue 
MAME (DDAH1 and AGXT2) transcript levels and eGFR decline in two 
independent human renal transplant cohorts (Table 1). In both the London 
and the Virginia cohort, there was a strong positive correlation between 
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corrected DDAH1 expression and corrected AGXT2 expression 
(supplementary data). Therefore for further analysis of eGFR decline we used 
a composite methylarginine gene expression calculated from the geometric 
mean of the DDAH1 and AGXT2 expression. In both cohorts, higher MAME 
expression was associated with a steeper decline in eGFR over the one year 
following allograft biopsy (Table 2). Although there was an association 
between MAME expression and baseline eGFR in the Virginia cohort this did 
not reach statistical significance in the London subjects. The multilevel 
approach allows estimation of the association between gene expression and 
eGFR decline independent of the baseline eGFR as illustrated in Figure 10.  
 
An association between kidney DDAH1 expression, NO activity and 
UMOD 
Given the findings of lower urinary UMOD peptide in proteomic analysis of 
Ddah1PT-/- mouse urine, we examined the association between DDAH1 gene 
expression and urinary UMOD protein concentration in the London patient 
cohort. Although there was only a trend toward a positive correlation in the 
cohort as a whole, a significant association between DDAH1 gene expression 
and urinary UMOD was observed when the analysis was restricted to 
recipients of live donor allografts (in order to minimise the impact of ischaemia 
and other confounding variables associated with deceased donor organs; 
Figure 11A; p=0.039).  
To establish whether the positive correlat on between renal DDAH1 
activity and UMOD protein expression observed in the Ddah1PT-/- mouse and 
human cohort was NO-dependent, we performed a further in vivo study in 
wild-type mice receiving a non-selective nitric oxide synthase (NOS) inhibitor 
(L-NG-Nitroarginine Methyl Ester; L-NAME). Changes in renal UMOD protein 
expression were assessed. Following two weeks of L-NAME treatment 
(1mg/mL dissolved in drinking water – concentrations previously established 
to systemically inhibit NOS in vivo 24-26), kidney tissue NOx (nitrites and 
nitrates) were reduced by 25% (p<0.01). Furthermore, UMOD protein 
expression was significantly reduced following L-NAME treatment; 40% in 
kidney tissue (p<0.01) and 30% in urine (p<0.01; Figure 11B-E).  
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Discussion 
We focussed this study on MAME activity limited to kidney tissue by exposing 
a novel transgenic mouse strain to two different forms of renal injury and 
examining renal biopsy and outcome data from two human cohorts. Our results 
lead us to conclude that local imbalances of the NO-ADMA-MAME axis may 
determine kidney function decline more reliably than circulating ADMA. 
Proximal tubule cell-specific DDAH1 deletion was dissociated from baseline 
plasma ADMA and systemic BP. The observed protection against kidney 
collagen deposition and functional decline was therefore independent of 
systemic confounders and distinguishes a critical difference between local 
(protective) and systemic (harmful) effects of ADMA in renal function decline. 
Data from two human renal transplant cohorts support the animal studies. 
Modeling renal function over time in the post-transplant period using laboratory 
values is not straightforward. Our estimates show substantial unexplained 
variation that was not significantly improved with addition of other clinical 
variables.  Despite this, we det cted an association between eGFR decline 
and increased MAME expression in both renal transplant cohorts. The 
relationship between the DDAH1 and AGXT2 enzymes is unclear but their 
relative expression was strongly correlated and a summary composite 
(geometric mean) of both the enzymes was used to demonstrate that raised 
kidney tissue MAME expression correlated with poorer outcomes in terms of 
eGFR.  
Our findings suggest a re-analysis of previously published human 
observational data showing that elevated plasma ADMA was associated with 
progression of renal disease. 19,20,27 Interestingly, in the largest study of CKD 
patients to date, no association was observed between serum methylarginine 
levels and renal progression once baseline GFR was taken into account. 19 
Previously, using a Mendelian randomisation approach (with less susceptibility 
to reverse causation and residual confounding), we reported a gene variant 
that conferred higher kidney tissue DDAH1 mRNA expression, and associated 
with more rapid renal decline. 21  
Previously published rodent studies of kidney fibrosis have reported that 
DDAH1 and NO are protective whilst ADMA is pathogenic, however significant 
study design issues limit their interpretation. ADMA or L-NAME infusion into 
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mice exacerbated renal fibrosis but both raised SBP by approximately 
60mmHg suggesting hypertensive injury, 28 whilst global DDAH1 
overexpression showed protection against fibrosis in angiotensin and surgical 
nephron-reduction models of CKD. 29,30 Genetic DDAH1 overexpression 
decreases circulating ADMA and introduces unmeasured effects upon normal 
regulatory mechanisms. Furthermore, DDAH1 overexpression occurs 
indiscriminately in cell types that do not normally express DDAH1, but play 
significant roles in inflammation and fibrosis (eg. macrophages). Here, PT-
specific DDAH1 gene deletion raises ADMA and reduces NO availability only 
within tubules and provides protection against fibrosis and functional decline in 
two different models of nephropathy.  
Proteomic urinalysis data in Ddah1PT-/- mice suggests that reduced 
tubular NO activity may confer protection against progressive fibrosis in folate 
and UUO nephropathy through reduced expression of collagen and UMOD 
proteins. A stimulatory role of NO activity upon collagen deposition and wound 
healing in skin and tendon tissue has been shown in in vitro and in vivo studies 
using exogenous NO donors, 31 iNOS overexpression 32 and even dietary L-
arginine supplementation. 33 Published literature confirms NO as a pleiotropic 
molecule in the kidney as well as other systems 34 with both protective and 
deleterious effects exerted by NO upon collagen deposition and fibrosis in 
renal disease. 35-39 What is clear is that maladaptive, pro-fibrotic responses to 
injury are at least in part, driven by cross-talk between high NO activity and 
fibrotic mediators such as TGFβ and matrix metalloproteases (MMPs) through 
SMAD signalling and other pathways. 37 Relevant to our own findings, 
pharmacological DDAH1 inhibition (causing reduced NO activity) has been 
demonstrated to reduce collagen deposition in a TGFβ and SMAD-dependent 
manner in a bleomycin model of pulmonary fibrosis. 40 
An association between urinary UMOD and renal DDAH1 expression was 
identified in both the Ddah1PT-/- mouse and human cohort data. An 8.5-fold 
reduction of UMOD in Ddah1PT-/- suggests that functional changes in MAMEs 
and NO synthesis within the proximal tubule are communicated downstream 
along the nephron to the thick ascending limb, where UMOD is exclusively 
expressed. 41 A link between NO activity and UMOD expression was confirmed 
in wild-type mice exposed to a non-selective NOS inhibitor (L-NAME), which 
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resulted in reduced UMOD protein expression in kidney tissue and urine. 
Interestingly, NO is known to exert regulatory control over two transcription 
factors; nuclear factor of activated T cells (NFAT) 42 and Oct-1, 43 both of which 
have consensus binding sites in the promoter region of UMOD. 44 These 
observations raise the possibility of direct regulation of UMOD expression by 
NO, a suggestion that certainly warrants further study. Genome-wide 
association studies (GWAS) identify a number of UMOD polymorphisms that 
associate with raised UMOD expression, hypertension, CKD and kidney 
function. 45 A recent report confirmed that common UMOD gene variants 
increase UMOD expression and that (salt-sensitive) hypertension and CKD 
progression may be induced through NKCC2 co-transporter stimulation. 46 In 
our study, reduced DDAH1 metabolism of methylarginines (in the proximal 
tubule) correlates with lower UMOD expression downstream and consistent 
with published data, may in part explain the protective effect observed against 
kidney disease progression.  
This study has several limitations. A minor degree of extra-renal (liver 
and brain) DDAH1 gene deletion in the Ddah1PT-/- mouse was suggested using 
sensitive PCR-based assays although this did not reach a level of statistical 
significance in DDAH1 mRNA transcription in these tissues. This may 
represent a constitutive leak of Cre expression autonomous of androgen 
stimulation, or Cre activation in response to even very low-levels of circulating 
testosterone in females. It is unlikely that such changes in neuronal or hepatic 
DDAH1 activity, in the absence of altered BP or systemic ADMA, could 
influence renal fibrosis. It is known that off-target Cre expression and activity is 
widely under-reported. 47 Cre toxicity has been reported to cause 
cardiomyopathy, 48 brain development defects 49 and widespread apoptosis in 
embryos. 50 To our knowledge, there are no descriptions of Cre-toxicity relating 
to fibrosis and any effects to date suggest that Cre acts to disrupt normal 
cellular function or architecture rather than preserve it, as seen in the Ddah1PT-
/- mouse. Other limitations such as relatively small patient sample numbers are 
counterbalanced by findings that are consistent across two very different 
experimental models of renal injury and human observational data examining 
gene expression and clinical outcomes in two independent cohorts. 
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In conclusion, we demonstrate that a reduction in renal ADMA 
metabolism protects against renal function decline in the context of renal injury. 
Whether therapeutic reduction of circulating ADMA would improve CV 
outcomes at the same time as accelerating renal fibrosis requires further 
investigation. Our findings suggest that, at least in the kidney, non-selective 
ADMA reduction could be detrimental.  
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Concise methods 
Animal studies 
Animal experiments and husbandry were performed under UK Home Office 
License after approval by the local ethics committee. The KAPiCre (KC) 
transgenic mouse on a C57B6 background was purchased from Jackson 
Laboratories (strain name: B6.Cg-Tg(Kap-cre)29066/2Sig/J). The ROSAYFP 
mouse (mixed background) was a kind gift from Professor Graham Williams 
(Imperial College, London). DDAH1 floxed mice on a mixed background were 
previously developed and supplied by our group. LoxP sites flank exon 1 of 
DDAH1 (exon 1 contains the initiating methionine codon and encodes the first 
100 amino acids of DDAH1 (approximately 35% of the total protein)). To 
achieve temporal activation of KC, female mice were treated with a 
subcutaneous testosterone pellet (Innovative Research of America, FL) for a 
minimum of ten days. Animals were placed in metabolic cages for a maximum 
of 24 hours and urine collected was centrifuged at 8,000 x g for 10 minutes, the 
supernatant stored at -80°C. 
Invasive blood pressure (IBP) recording was performed under terminal (1%) 
isoflurane anaesthesia. A ‘Mikro-Tip’ pressure transducer catheter (Millar 
Instruments, TX) placed into the carotid artery. Recordings were obtained 
using the Powerlab system with analysis on Chart software (both 
ADInstruments, Oxfordshire, UK).  
Folate nephropathy. Mice received a single intra-peritoneal injection of folate 
(240µg/g) dissolved in 0.3M NaHCO3 vehicle (20mg/mL) or vehicle control 
alone (both from Sigma, Dorset, UK). Mice were sacrificed by CO2 narcosis 
and cervical dislocation at day 2, day 14 or day 84 (12 weeks). Blood collected 
by direct cardiac puncture was stored on ice before centrifugation at 8,000 x g 
to remove plasma. The right kidney was halved (sagittal plane) for histology, 
and quartered for future RNA and protein extraction while the left kidney was 
weighed. Samples were stored at -80°C.  
Unilateral ureteric obstructive (UUO) nephropathy. Under isoflurane 
inhalation anaesthesia, mice were shaved, draped and positioned on a heat 
mat. In the supine position, a left flank incision exposed the left ureter and was 
ligated twice with 4-0 nylon sutures and transected. Following suture closure, 
animals received intramuscular diclofenac analgesia (Vetagesic) and 
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recovered in heated chambers. Mice were sacrificed by cervical dislocation 
followed by organ harvesting at three time points; 1, 2 and 3 weeks. 
L-NAME experiment. Female littermate wild-type C57BL/6 mice aged 
approximately 10 weeks old were randomly allocated to receive either plain 
deionized drinking water or the same water containing dissolved L-NG-
Nitroarginine Methyl Ester (L-NAME; 1mg/mL, Enzo Life Sciences). n=8 in 
each group. Water was changed every three days and mice were sacrificed by 
CO2 narcosis and cervical dislocation. Urine was collected for 24 hours prior to 
sacrifice and kidney tissue was harvested, snap frozen in liquid nitrogen and 
stored at -80°C before further analysis. 
Renal tubule isolation. Mice were sacrificed by CO2 narcosis and cervical 
dislocation, the abdominal aorta was ligated superior to the renal arteries and 
magnetic beads (Dynabeads M-450 Tosylactivated, Invitrogen, Paisley, UK) 
suspended in ice-cold HBSS were infused via an aortic catheter placed distally 
and kidney perfusion confirmed by rapid blanching. Kidneys were then 
dissected out, decapsulated and minced with a scalpel before incubation in 
collagenase (1mg/mL, Sigma, Dorset, UK) at 37°C for 30mins with agitation. 
The resulting homogenate was successively sieved through 100µ and 50µ 
pore sizes and fragments caught by the latter were resuspended in cold HBSS. 
Magnetic separation of glomerular and tubular fragments was confirmed by 
microscopic examination (bead entrapment visible within glomerular capillary 
loops). Purified tubules were pelleted by centrifugation at 1000 x g and stored 
at -80°C for future use or subjected to further digestion (Accumax; protease / 
DNAse solution; Innovative Cell Technologies Inc, CA) prior to ImageStream 
analysis (Amnis, WA). Cells were gated according to spherical shape and 
yellow fluorescence before automated single-cell image capture. 
Biochemical methods 
LCMSMS. The Agilent 6400 Series Triple Quadrupole LCMS/MS System was 
used for this study. Biological compounds optimised for detection included 
methylarginines (Calbiochem, Nottingham, UK), amino acids; creatinine (all 
Sigma, Dorset, UK). Biological samples including plasma, urine and tissue 
lysates were prepared by methanol protein precipitation in a 1:5 dilution, 
vortexed and the pellet removed by centrifugation. Sample solutions were 
evaporated to dry in a heat-block and resuspended in mobile phase (0.1% 
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formic acid). An internal standard was added (7-deuterated ADMA; Cambridge 
Isotope Laboratories, MA) before precipitation to allow correction for extraction 
efficiency and ion suppression at the point of detection (ions in large 
abundance can out-compete minority ions at the detector). A hypercarb 
(Thermo Scientific, UK) chromatography column was used and the mobile 
phase consisted of 0.1% formic acid, 1% acetonitrile (increasing to 50% 
between 5 and 10 minutes) over a total run time of 15 minutes. Data was 
collected using Agilent (Berkshire, UK) MassHunter Data Acquisition Software 
and analysed with MassHunter Qualitative Analysis Software before 
downloading raw data into MicroSoft Excel for processing. The mass spectrum 
parameters were as follows: ADMA, mass-to-charge ratio (m/z): 203.3 to 46.0, 
collision energy (CE): 12; SDMA, m/z: 203.3 to 70.2, CE: 24; arginine, m/z: 
175.2 to 60.1, CE: 8; citrulline, m/z: 176.2 to 86.2, CE: 16; glutamine, m/z: 
147.0 to 56.3, CE: 0; d7-ADMA, m/z: 210.0 to 46.0, CE: 24; creatinine m/z: 
114.0 to 44.0, CE: 12. Standard curves were generated for each substance of 
interest.  
Molecular biological methods 
Measurements of routine biochemical variables in patient samples were 
performed by National Health Service hospital laboratories. NOx (NO2 and 
NO3) was measured by chemiluminscence with a Sievers Nitric Oxide 
Analyzer (GE Analytical Instruments, Manchester, UK) as per protocol. Protein 
concentrations were determined by Bradford assay and Nanodrop. 
Tissue genotyping was performed using ReadyMix Taq PCR Reaction Mix 
(Sigma, Dorset, UK). Tissue mRNA expression was determined by iScript 
cDNA reverse transcription kit, followed by RT-qPCR (iTaq Fast SYBR Green 
Supermix with ROX (BioRad, Hertfordshire, UK) using a 7900HT Fast System, 
Applied Biosystems (Life Technologies, Paisley, UK). All reactions were 
performed in duplicate and several “housekeeper” sequences were optimised 
for different types of biological sample with Pol2a the most stably expressed 
gene. Primer sequences are listed in the complete methods. 
Proteins were separated and identified using Western Blotting and sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to 
standard protocols. A polyclonal goat DDAH1 antibody was produced by our 
own group. UMOD antibody was purchased from R & D Systems (MN, USA). 
Page 15 of 60
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
GAPDH antibody was purchased from Sigma (Dorset, UK) and the Licor 
Odyssey system (UK) used for protein detection and quantification. Mouse 
urine UMOD protein was quantified by ELISA according to manufacturers’ 
protocol (Uscn Life Science Inc., PRC). 
Histological methods 
Frozen sections. Kidneys from the ROSAYFP reporter mouse were fixed 
overnight in 4% PFA, then 30% sucrose in PBS until full tissue submersion (~4 
hours). Specimens were embedded in OCT and snap frozen onto cork discs in 
methanol cooled on dry ice and stored at -80°C. Sections (5 µM) were cut at -
20°C (cryotome CM 1850 Leica Microsystems, Germany) onto poly-L-lysine-
coated glass slides. Slides were studied using a Leica SP5 microscope. 
Paraffin sections. Harvested organs were fixed in 4% paraformaldehyde 
(PFA) overnight and then stored in 70% ethanol. Tissues were embedded in 
paraffin blocks by an automated processor and 5µM sections cut on a 
microtome and attached to poly-L-lysine-coated glass slides before staining 
with periodic-acid schiff or picrosirius red (PSR). 
Collagen content. Kidney sections were assessed for collagen deposition 
using a Manual Zeiss Axiophot microscope (Zeiss, NY) through circularly 
polarized light. Tissue images were obtained with a 2.5X objective lens, 
recorded on a digital camera (Canon EOS-40D digital SLR; Canon Inc, Tokyo, 
Japan) and viewed through Canon Utilities EOS software (Canon Inc, Tokyo, 
Japan). Images were analysed using a Fiji software macro (written by Dr Dirk 
Dorman, Head of Microscopy, MRC Clinical Sciences Centre, Imperial College, 
London) to quantify collagen in each whole kidney slice, thus obviating bias. 
Percentage collagen deposition per total section area (pixels) could then be 
reported.  
Statistical methods. Statistical analysis was performed using the Prism 
software package (Graph Pad Inc., UK). All data are presented as means ± 
SEM. For comparisons between two groups for a single variable, a Mann-
Whitney U test (non-parametric data or where a normal distribution could not 
be assumed) was used. Differences between multiple groups were assessed 
by one-way analysis of variance (ANOVA) followed by Bonferroni’s post test for 
multiple comparisons. Two-way ANOVA was used where comparisons were 
being made between groups subject to two experimental variables, followed by 
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Bonferroni’s post test for multiple comparisons. P values of <0.05 were 
considered statistically significant. 
Proteomic analysis (LC-MS/MS) 
Urine samples were retrieved from -80°C and thawed in an Eppendorf 
Thermomixer Comfort mixer at 22ºC, 900 x g for 10 minutes, and then 
centrifuged at 5ºC, 13000g for 3 minutes. 200µL of sample was mixed 1:5 with 
0.1% trifluoroacetic (TFA) acid and subjected to two different solid phase 
extraction (SPE) steps; reverse-phase SPE (Waters Oasis HLB cartridges, 
Waters Corporation, MA) and; cation exchange SPE (Waters Oasis MCX 
cartridges, Waters Corporation, MA). SPE was performed using a manual 
vacuum manifold (24 port vacuum manifold, Thermo Scientific, DE) & LC-MS 
grade solvents (Fisher Scientific, UK). Dried samples were solubilised in 40µL 
of 0.1%TFA, sonicated for 10 minutes and then centrifuged at 5ºC, 13000g for 
10 minutes. 10µL of supernatant was transferred to a Bioquote Limited 0.2mL 
lubricated hydrophobic PCR tube and placed into an autosampler vial ready for 
LC-MS injection and analysis. A Dionex (Thermo Scientific, DE) Ultimate 3000 
nano liquid chromatography system was used to separate peptides prior to 
mass spectrometric analysis. A volume of 4µL was loaded onto a trap column 
(Acclaim Pepmap 100, Thermo Scientific, DE) at 8µL/min in 98% water, 2% 
acetonitrile, 0.1% TFA. Peptides were then eluted on-line to an analytical 
column (Acclaim Pepmap RSLC, Thermo Scientific, DE) and separated using a 
ramped gradient with conditions: initial 5 minutes with 4% B (96% A), then 90 
minute gradient 4-55% B, then 10 minute isocratic at 100% B, then 5 minute 
isocratic at 4% B (solvent A: 98% water, 2% acetonitrile, 0.1% formic acid; 
solvent B: 20% water, 80% acetonitrile, 0.1% formic acid). Eluted peptides 
were analysed using LTQ XL Orbitrap (Thermo Scientific, DE) operating in 
positive polarity, top 4 CID (collision-induced dissociation) method. Ions for 
dissociation were determined from initial 15000 resolution MS scan (event 1) 
followed by CID on the top 4 most abundant ions. CID conditions: default 
charge state 2, 2.0 m/z isolation width, normalised collision energy 35.0, 
Activation Q value 0.25, activation time 30ms, lock mass value of 445.120030 
m/z used. 
Proteomic data analysis. Raw files were searched against UniprotKB/Swiss-
Prot database (version 10032012) restricted to mouse entries using Mascot 
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v2.3.01. Relative quantification of peptides was performed by extracted ion 
chromatograms of parent ions using an in-house developed software. 
Human cohort data methods 
Participants. Appropriate research ethics committee, NHS management, and 
institutional review board approvals were in place for both cohort studies. 
Studies were conducted in accordance with the Declaration of Helsinki 
Principles and written informed consent was obtained from all subjects. 
The London Protocol Biopsy Study consisted of patients undergoing protocol 
biopsy following first kidney alone transplant as per routine clinical care.  
Subjects were recruited from the Royal Free Hospital NHS Trust transplant 
clinic. The Virginia cohort underwent similar protocol biopsies but two patients 
with kidney after liver transplant were also included. Follow-up biochemistry 
was performed in local laboratories as per routine clinical care and eGFR 
results obtained with a minimum interval of 1 week between data-points in the 
London study and monthly in the Virginia study.   
Biopsy Tissue RT-qPCR. Protocol biopsy samples were preserved in ‘RNA 
Later’ (Qiagen, UK) at the bedside, before being stored at -70°C. Tissue was 
lysed in a 1% β-mercaptoethanol (β-ME) containing proprietary lysis buffer 
(RLT, Qiagen, UK). RNA was extracted using a column system (RNeasy kit, 
Qiagen, UK) according to the manufacturer’s instructions. No carrier RNA was 
used.  Resulting RNA samples were examined using a ‘Nanodrop’ 
spectrophotometer (Thermo Scientific, DE) prior to reverse transcription. First 
strand cDNA was synthesized using qScript cDNA Synthesis Kit (Quanta 
Biosciences, MD). 
In the London cohort primers were designed to amplify cDNA from human 
DDAH1. Primer sequences for human control genes were either publically 
available, or listed elsewhere. 21 Absolute quantification of cDNA was 
performed on a 7900HT Real-Time PCR System (Applied Biosystems, Life 
Technologies, UK).  RT-qPCR results from the genes of interest were 
normalised to the 3 most stable of 6 control genes ACTβ, β-2 microglobulin 
(β2M), hypoxanthine phosphoribosyltransferase 1 (HPRT), ribosomal protein 
13A (RPL13A), succinate deghydrogenase complex subunit A flavoprotein 
(SDHA) and TATA box binding protein (TBP). In the Virginia cohort a taqman 
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primer approach was used. Expression of DDAH1 and AGXT2 were performed 
and corrected to a single reference gene (beta-2 microglobulin). In both 
cohorts genes of interest were normalized to vary between zero and one. Ten 
samples were quantified at both sites demonstrating high levels of inter-centre 
agreement.  
Uromodulin in the human cohort was measured using ELISA (MD Bioproducts, 
Zurich) as per manufacturer’s instructions.  
Human cohort data statistical methods. A multilevel multivariable approach 
was used to model eGFR over time in each of the two cohorts. Follow-up was 
commenced at the time of protocol biopsy and MDRD GFR measurements out 
to 1-year following biopsy examined. eGFR values were nested within patients 
using both a random-intercept and random-slope and the slope of eGFR 
quantified by the inclusion time variable.  The impact of gene expression on 
eGFR decline was quantified by the addition of an expression x time 
interaction. Residuals were xamined to ensure there was no substantial 
deviation from normality.  
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London 
 
Virginia 
 
Sex, n (%) female 19 (51.35) 14 (38.9) 
Age, median (IQR) 
 
47 (40 to 58) 55 (44.5 to 61) 
Ethnicity, n (%) south asian 4 (10.81) 0 (0) 
 
black 13 (35.14) 7 (19.4) 
 
other  3  (8.11) 1 (2.8) 
 
white 17 (45.95) 28 (77.8) 
Donor type, n (%) live 9 (24.32) 1 (2.8) 
Donor age, median (IQR) 
 
53 (48 to 61) 47 (23 to 53) 
DGF, n (%) 
 
21 (56.75) 14 (38.9) 
Rejection prior to protocol biopsy, n (%) 0 (0) 1 (2.8) 
eGFR at biopsy, mean (SD ) 
 
52.9 (17.7) 56.2 (19) 
UMOD, median (IQR) 
 
8.1 (2.7 to 15.2) 
  
 
Table 1. Demographics of two human renal transplant cohorts. 
DGF, delayed graft function. eGFR, estimated glomerular filtration rate. UMOD, uromodulin.
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London Virginia 
Estimate 95% CI Estimate 95% CI 
GFR change over time mL/min/1.72m2 per 
day 0.032 0.014 to 0.049 -0.01 -0.025 to 0.005 
Increase in GFR at biopsy mL/min/1.72m2 
per unit MAME 16.2 -7.3 to 43.4 32.7 13.4 to 52.0 
Change in GFR over time per 
mL/min/1.72m2 per unit MAME per day  -0.065 -0.107 to -0.023 -0.050 -0.098 to -0.001 
 
Table 2. Standard deviation of eGFR estimates: (i) between subject at baseline (intercept): 
London, 16.2ml/min per 1.73m2 (95% CI, 12.8-20.6); Virginia, 14.9ml/min per 1.73m2 (95% 
CI, 11.4-19.5); (ii) between subject over time (slope): London, 0.02ml/ min per 1.73m2 per day 
(95% CI, 0.01–0.03); Virginia, 0.03ml/min per 1.73m2 per day (95% CI, 0.02-0.05); (iii) within 
subject: London, 7.1ml/min per 1.73m2 (95% CI, 6.6–7.5); Virginia, 7.3ml/min per 1.73m2 
(95% CI, 6.8-7.9). Correlation between baseline eGFR (intercept) and slope: London: 0.06 
(95% CI, -0.49-0.57); Virginia: 0.17 (95% CI, -0.25-0.54). A decline of 0.05-0.065 
mL/min/1.72m2/day per unit MAME may appear trivial, but a 50% higher renal MAME 
expression would be reflected in an additional annual rate of renal function decline of 9-12.0 
mL/min/1.72m2 (MAME expression units across these cohorts were normalized to values 
between 0 and 1). 
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Figure 1. Immunohistochemical staining for DDAH1. Human allograft protocol biopsy 
tissue. A, DDAH1 staining is seen in the epithelial cells of the proximal tubule (arrows) and 
not in the glomerulus (g) or control (B; DDAH1 antibody pre-incubated with DDAH1 peptide). 
A B 
g 
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Figure 2. Generation of the ROSAYFP 
reporter mouse (A-C) and Ddah1PT-/- 
mouse strains (D-H). 
A, Schematic of conditional YFP expression 
in the reporter mouse. B, ImageStream flow 
cytometry reveals YFP expression in renal 
tubular cells isolated from the KAPiCre+ 
genotype but not KAPiCre-. R2 gating for 
sphericity, R4 gating for fluorescence. 
Brightfield and yellow fluorescent single cell 
images are displayed (B, KAPiCre+). C, YFP 
fluorescence visible in unstained kidney 
sections from KAPiCre+ mice and not 
KAPiCre-. Representative of n=3. Bars = 50 
µm. 
D, Schematic of conditional Ddah1 deletion 
in the Ddah1PT-/- mouse. E, Kidney tissue 
end-point PCR genotyping for KAPiCre (KC), 
floxed Ddah1 and deleted Ddah1 sequences 
reveals gene excision in KAPiCre + 
(Ddah1PT-/-) but not KAPiCre– (Ddah1fl/fl) 
genotypes (2 per genotype shown for 
representation). Excision is detected within 
liver and brain, however quantitative RT-
qPCR analysis reveals significant Ddah1 
mRNA reduction within kidney but not other 
organs (F). G, Kidney tissue DDAH1 protein 
(4 for representation in Western blot) and H, 
enzymatic activity are significantly reduced 
(70-80%). Mann-Whitney U test, n=6 
(Ddah1fl/fl) and n=8 (Ddah1PT-/-), *p<0.05 
***<0.001.  
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Figure 3. Effects of PT-specific Ddah1 deletion upon ADMA and NO are tubule-specific. 
A and B, tubular cells isolated from Ddah1PT-/- mice contained significantly higher ADMA and 
lower NO concentrations. SDMA, a methylarginine not a substrate for DDAH1, was 
unaffected. C-H, these changes were not evident in whole kidney tissue, plasma or urine. I, 
Tubular cell expression of other MAMEs and NOS isoforms (neuronal, inducible and 
endothelial), was unaffected in Ddah1PT-/- mice. Similarly, systolic BP, plasma creatinine and 
urinary volumes were not altered (J-L). Mann-Whitney U test, n=6 each group, *p<0.05. 
(NOTE: The measurement of urinary NOx is not necessarily an accurate determination of 
renal NOS activity, particularly in the context of a nitrate-containing diet). 
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Figure 4. Effects of PT-specific Ddah1 deletion upon urinary electrolytes, protein and 
amino acids at baseline. No consistent changes in urine biochemistry were identified in 
Ddah1PT-/- mice. Amino acids L-citrulline and L-arginine being product and substrate for NO 
synthesis respectively; L-glutamine was selected due to abundance in urine and has been 
shown to be elevated in patients with tubular dysfunction (Fanconi’s syndrome). 51 All values 
corrected for creatinine concentration. Mann-Whitney U test. n=8 (Ddah1fl/fl) and n=20 
(Ddah1PT-/-). 
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Figure 5. Heat map of urinary proteomic analysis following PT-specific Ddah1 deletion at baseline. 82 of 1057 peptides screened were significantly 
altered by Ddah1 deletion. The ten most significantly down- and upregulated peptides are represented here. (q values represent values of significance 
adjusted for multiple comparisons, n=4).
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Figure 6. Histological appearances of folate nephropathy in Ddah1PT-/- mice and controls. At 2 days and 2 weeks following a single IP folate injection, 
significant disease was evident including; tubular dilatation (td) and epithelial cell flattening; luminal casts (lc) and more significantly at 2 weeks; 
tubulointerstitial inflammatory cell infiltrates (inc). At 12 weeks following folate injury, tubulointerstitial fibrosis / extra-cellular matrix (ecm) deposition was 
evident. There were no gross histological differences between Ddah1fl/fl and Ddah1PT-/- mice however, analysis of collagen deposition and pro-fibrotic cytokine 
gene expression revealed protection from PT-specific Ddah1 deletion (Figure 7). Images representative of n=9 (Ddah1fl/fl), n=12 (Ddah1PT-/-). Bars = 50 µm. 
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Figure 7. Effects of PT-specific DDAH1 deletion at 12 weeks following folate. A, Renal 
collagen deposition was significantly reduced in Ddah1PT-/- mice versus Ddah1fl/fl controls (4.5 
vs 7.2%; p<0.05). Two-way ANOVA with Bonferroni’s post test, *p<0.05. B, Ddah1PT-/- mice 
had significantly attenuated kidney:body weight ratio reduction compared to Ddah1fl/fl controls 
(p<0.001; values are deviations from means of vehicle-treated controls). C, RT-qPCR 
analysis revealed significantly lower renal tissue pro-fibrotic cytokine expression in Ddah1PT-/- 
mice. Collagen 1 subunit α2 (Col1α2) >3-fold (p<0.05); transforming growth factor β (TGFβ) 
>5-fold (p<0.01); and endothelin-1 (ET-1) almost 3-fold (p<0.05). D and E, systolic BP and 
serum creatinine were lower in Ddah1PT-/- mice (**p<0.01 and ***p<0.001 respectively). F, 
proteinuria according to urine protein:creatinine ratio (UPCR) was reduced in Ddah1PT-/- mice 
but not statistically significant. Mann-Whitney U test unless otherwise stated, n=9 (Ddah1fl/fl) 
and n=12 (Ddah1PT-/-). *p<0.05, **p<0.01, ***p<0.001.  
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Figure 8. Reduced renal collagen deposition in PT-specific DDAH1 deleted mice at 12 
weeks following folate. Kidney sections stained with picrosirius red and viewed through 
circularly polarised light. Images taken at x25 magnification were processed using Image J 
software. Images were stitched to produce a complete kidney section image, total section 
area defined by texture thresholding and collagen (yellow) was quantified as a percentage of 
total kidney section area. n=3 shown here representative of n=9 (Ddah1fl/fl) and n=12 
(Ddah1PT-/-).  
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Figure 9. Effects of PT-specific DDAH1 deletion at two weeks following UUO  
A and B, Renal collagen deposition was significantly lower in than Ddah1fl/fl controls 
(determined by non-biased software analysis of picrosirius red stained sections; 6.6 vs 
10.4%; p<0.05). C, Renal parenchyma was less contracted in Ddah1PT-/- mice (assessed by 
percentage reduction of whole kidney section area (compared to unobstructed contralateral 
kidney in same mouse; 35 vs 47% in Ddah1fl/fl controls; p<0.05). C, RT-qPCR analysis 
revealed significantly lower renal tissue pro-fibrotic cytokine expression in Ddah1PT-/- mice. 
Collagen 1 subunit α2 (Col1α2) >4-fold (0.07 vs 0.29 AU in Ddah1fl/fl controls; p<0.05); 
transforming growth factor β (TGFβ) 2-fold (0.19 vs 0.37 AU in Ddah1fl/fl controls; p<0.05); 
and endothelin-1 (ET-1) by ~40% (0.22 vs 0.35 AU; not statistically significant). Mann-
Whitney U test, n=13 (Ddah1fl/fl) and n=20 (Ddah1PT-/-). *p<0.05. 
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Figure 10. Relationship between kidney tissue MAME expression and eGFR decline in 
renal transplant recipients. 
Estimates of [change in] eGFR over time in London cohort stratified by MAME expression 
(above or below median) derived from the multilevel model. Dotted line, MAME expression 
below median; solid line, MAME expression above median 
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Figure 11. Relationship between DDAH1  gene expression, NO activity and UMOD protein expression 
A, Renal biopsy tissue DDAH1 mRNA expression positively correlated with urinary UMOD in live donor allografts (p=0.039). When extended to the whole 
cohort, the association was rendered statistically insignificant which likely reflects the heterogeneity of organs from deceased donors.  B – D, non-
selective NOS inhibition with L-NAME dissolved in drinking water (1mg/mL for two weeks) in wild-type C57BL/6 mice.  B, L-NAME-treated mice had 
significantly reduced kidney tissue NOx (p<0.01; determined by chemiluminescence) and significantly lower UMOD protein expression in urine (C, p<0.01; 
by ELISA) and kidney tissue (D,E, p<0.01; Western blot; n=3 representative of 8 in each group). Mann-Whitney U test. **p<0.01. 
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Supplementary material !
1 HUMAN COHORT DATA 
1.1 DDAH1 alone 
DD1#
#
London#
# #
Virginia#
# #
# #
Estimate# 95%## CI# Estimate# 95%## CI#
GFR#change#over#time#mL/min/1.72m2#per#
day# 0.023# 0.005# 0.041# 0.011# F0.015# 0.038#
# # # # # # # #Increase#in#GFR#at#biopsy#mL/min/1.72m2#
per#unit#DD1# 17.099# F5.043# 39.241# 17.738# 8.972# 26.503#
Change#in#GFR#over#time#per#
mL/min/1.72m2#per#unit#DD1#per#day## F0.046# F0.091# 0.000# F0.048# F0.101# 0.005#
 
Standard deviation of eGFR estimates: (i) between subject at baseline (intercept): London, 
16.0ml/min per 1.73m
2 (95% CI, 12.6–20.2); Virginia, 14.1ml/min per 1.73m
2 (95% CI, 10.8-
18.5); (ii) between subject over time (slope): London, 0.02ml/ min per 1.73m
2
per day (95% CI, 
0.01–0.04); Virginia, 0.04ml/min per 1.73m
2 per day (95% CI, 0.03-0.05); (iii) within subject: 
London, 7.1ml/min per 1.73m
2 (95% CI, 6.7–7.5); Virginia, 7.3ml/min per 1.73m
2 (95% CI, 
6.8–7.9). Correlation between baseline eGFR (intercept) and slope: London: 0.01 (95% CI, -
0.48-0.50); Virginia: 0.18 (95% CI, -0.24-0.55). 
1.2 AGXT2 alone 
AGXT2#
#
London#
# #
Virginia#
# #
# #
Estimate# 95%## CI# Estimate# 95%## CI#
GFR#change#over#time#mL/min/1.72m2#per
day# 0.032# 0.015# 0.049# 0.013# F0.012# 0.038#
# # # # # # # #Increase#in#GFR#at#biopsy#mL/min/1.72m2#
per#unit#MAME# 13.221# F9.611# 36.052# 19.219# 0.924# 37.513#
Change#in#GFR#over#time#per#
mL/min/1.72m2#per#unit#MAME#per#day## F0.060# F0.096# F0.023# F0.045# F0.086# F0.003#
 
Standard deviation of eGFR estimates: (i) between subject at baseline (intercept): London, 
16.4ml/min per 1.73m
2 (95% CI, 12.9–20.8); Virginia, 16.1ml/min per 1.73m
2
 (95% CI, 12.5-
21.1); (ii) between subject over time (slope): London, 0.02ml/ min per 1.73m
2 per day (95% 
CI, 0.01–0.03); Virginia, 0.03ml/min per 1.73m
2 per day (95% CI, 0.02-0.05); (iii) within 
subject: London, 7.0ml/min per 1.73m
2 (95% CI, 6.6–7.5); Virginia, 7.3ml/min per 1.73m
2 
(95% CI, 6.8–7.9). Correlation between baseline eGFR (intercept) and slope: London: 0.03 
(95% CI, -0.50-0.54); Virginia: 0.11 (95% CI, -0.30-0.50) 
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1.3 Plasma ADMA correlation with kidney tissue DDAH1 expression 
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ln
 p
la
sm
a 
AD
M
A
. regress log_pl_adma reldd1 relagxt2
                                                                              
       _cons    -.1283758   .1115929    -1.15   0.258    -.3554133    .0986617
      reldd1    -.5633755   .2495867    -2.26   0.031    -1.071164   -.0555875
                                                                              
 log_pl_adma        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
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2 CHARACTERISATION OF THE FOLATE NEPHROPATHY MODEL  
2.1 Introduction 
Folate (folic acid or pteroylglutamic acid) is an essential cofactor required for 
the synthesis of pyridines and pyrimidines to create DNA. Freely filtered at the 
glomerulus, folate is actively reabsorbed in the proximal tubule by specialised 
transport proteins (α-folate receptor proteins, α-FRs). 1 Supplementary oral 
folate is routinely prescribed for patients with ESRD on haemodialysis, 
malnourished patients, and pregnant women. 
Administration of intraperitoneal (IP) folate is a well-established 
experimental technique to model renal injury. 2-4 When folate is administered 
in supra-therapeutic doses (180-240µg/g; ~15,000-fold higher than the 5mg 
daily prescribed dose in haemodialysis patients), folate crystals precipitate 
within renal tubule lumina and induce dose-dependent nephrotoxicity.  
Widespread acute tubular necrosis ensues within 48 hours with a concomitant 
rise in serum creatinine and BUN to mimic AKI. A period of epithelial 
regeneration follows, and from 2 weeks following injury, the kidneys exhibit 
progressive fibrosis and loss of function. Folate injury thus provides a 
reproducible model with which to examine the natural history of inflammation 
from initiating acute tubular injury through to slowly progressive fibrosis 
characteristic of chronic kidney disease. 
Prior to adopting folate nephropathy as the model for CKD in this study, 
it was necessary to characterise the course of folate-induced renal disease 
and assess the quality of data that could be gained using a variety of analysis 
techniques. 
2.2 Study design 
Forty, 10-week old female WT C57BL6 littermate mice were purchased from 
Charles River Ltd (Kent, UK) and randomly assigned to receiving a single IP 
injection of either vehicle (0.3M NaHCO3) or folate (240µg/g, dissolved in 
0.3M NaHCO3). Mice were sacrificed at 2 days, 2 weeks and 12 weeks. A 
detailed description of tissue harvesting can be found in the Methods chapter. 
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Group sizes were between 5-8 (no premature deaths were experienced in this 
study). 
2.3 Results 
2.3.1 Kidney : body weight ratio and appearance 
The kidney : body weight ratio changed appreciably over the course of the 
disease: initially increasing by 30% at day 2 (<0.0001) with a pale, swollen 
appearance (Figure 1A), followed by a return to baseline weight at 2 weeks 
(Figure 1B). At 12 weeks following folate injection, the kidneys had shrunk to 
30% less than vehicle-treated controls with a pale, shrivelled appearance 
(Figure 1C). 
 
Figure 1. Kidney : body weight and appearance in folate nephropathy 
Photographs of harvested kidneys (left-sided) following vehicle vs folate administration at (A) 
2 days; 6.2 vs 8.4 mg/g (95% CIs 5.3-7.2 and 7.7-9.1); p<0.0001. (B) 2 weeks; both 6.2 mg/g. 
(C) 12 weeks; 6 vs 4.1 mg/g (95% CIs 5.6-6.4 and 3.7-4.4); p<0.0001. Three kidneys imaged 
to represent; vehicle-treated n=5; folate-treated n=8. (D) Graphical representation of kidney : 
body weight ratios (milligrams per gram, mg/g). Two-way ANOVA with Bonferroni’s post test.  
n=5 (vehicle), n=8 (folate) ***p<0.0001. 
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2.3.2 Serum and urinalysis 
At 2 days following folate administration, serum creatinine rose significantly 
(16-fold; p<0.001) over vehicle-treated animals, falling to 3-fold higher at 2 
weeks (p<0.05) and remained 2-fold higher than controls at 12 weeks 
(p<0.05) (Figure 2). 
Figure 2. Serum creatinine (A), urine output (B) and proteinuria (C) in folate 
nephropathy 
Serum creatinine was quantified by LC-MS/MS. (A) Serum creatinine (vehicle vs folate) at 2 
days; 17 vs 276 µM (95% CIs 11-24 and 249-302); p<0.001. 2 weeks; 24 vs 65 µM (16-31 
and 43-87); p<0.05. 12 weeks; 19 vs 34 µM (15-24 and 20-47); p<0.05. (B) Urine output was 
elevated at 2 weeks; 1.8 vs 9.9 mL/g/hr (1.2-2.5 and 6.5-13.3); p<0.001. (C) Proteinuria was 
raised at 2 weeks and fell by 12 weeks (not statistically significant between treatment groups). 
Two-way ANOVA with Bonferroni’s post test. n=5 (vehicle), n=8 (folate). *p<0.05 ***p<0.001. 
 
For humane reasons, housing mice in metabolic cages was avoided 
during the period of acute inflammation hence urinary data at 2 days are not 
available. Mice treated with folate displayed significant polyuria at 2 weeks (5-
fold; p<0.001), which reduced to a level marginally above vehicle-treated 
controls at 12 weeks (non-significant). Proteinuria, reported as urinary protein-
creatinine ratio did not significantly change at either time point.  
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2.3.3 MAME expression, MAs and NO activity 
Kidney tissue mRNA expression of both DDAH isoforms (1 and 2) and AGXT2 
was altered during the course of folate-induced kidney disease (Figure 3). 
DDAH1 expression was reduced at 2 and 12 weeks although this was not 
statistically significant. DDAH2 expression did not change until 2 weeks with 
~3-fold upregulation (p<0.001), persisting at 12 weeks (p<0.01). AGXT2 
expression fell 37-fold at 2 days following folate in comparison to vehicle 
treatment (p<0.001), recovering to baseline by 12 weeks.  
 
Figure 3. Whole kidney tissue MAME and iNOS expression in folate nephropathy 
mRNA expression measured by RT-qPCR. (A) DDAH1 expression did not change 
significantly although there was a trend towards downregulation at 2 and 12 weeks following 
folate. (B) DDAH2, 2 weeks 0.3 vs 0.8 AU (95% CIs 0.2-0.4 and 0.5-1.2); p<0.001. 12 weeks 
0.3 vs 0.6 AU (0.2-0.3 and 0.4-0.7); p<0.01. (C) AGXT2, 2 days 14.6 vs 0.4 AU (4.8-24.3 and 
0.3-0.5); p<0.001. 2 weeks 14.7 vs 6.7 AU (10.6-18.7 and 1.4-12.0); p<0.05. 12 weeks, non-
significant. Two-way ANOVA, *p<0.05, **p<0.01, ***p<0.001. 
In response to folate renal injury, methylarginine concentrations in plasma, 
urine and whole kidney tissue changed over time (Figure 4). At 2 days, 
plasma L-NMMA and SDMA rose significantly in response to folate 
administration (8- and 4-fold respectively; p<0.001) and quickly fell towards 
baseline at 2 and 12 weeks. ADMA plasma concentrations did not alter at 2 
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days and although trended towards a rise at 2 and 12 weeks, did not increase 
significantly. 
 
 
Figure 4. Methylarginine (MA) content in plasma, urine and whole kidney in folate 
nephropathy 
MAs measured by LC/MSMS. (A) Plasma L-NMMA and (C) SDMA were elevated at 2 days. 
L-NMMA (vehicle vs folate), 418 vs 3356 AU (95% CIs 72-764 and 2566-4145); p<0.001. 
SDMA, 4551 vs 18290 AU (1925-22753 and 13310-23270); p<0.001. (D) Urinary L-NMMA at 
2 weeks, 209 vs 488 AU (138-280 and 266-710); p<0.05. (E) Urinary ADMA at 2 weeks, 
80415 vs 53466 AU (61529-99301 and 42868-64065); p<0.01. (F) Urinary SDMA at 2 weeks, 
36500 vs 23530 AU (26990-46010 and 16860-30199); p<0.05, similar effect remained at 12 
weeks. (G) Kidney L-NMMA was elevated at 2 days 690 vs 1707 (392-988 and 1371-2043); 
p<0.001 and fell to non-significantly elevated levels at 2 and 12 weeks. (H) Kidney ADMA was 
elevated at every time-point with a peak at 2 weeks, 5978 vs 11258 AU (3856-8100 and 
9837-12679); p<0.001. (I) Kidney SDMA was most elevated at 2 days, 321 vs 557 AU (200-
442 and 323-791); p<0.05 and fell to control levels by 12 weeks.  Two-way ANOVA with 
Bonferroni’s post test. n=5 (vehicle), n=8 (folate).  *p<0.05, **p<0.01, ***p<0.001. 
 
 
In urine, L-NMMA was elevated 2.5-fold (p<0.05) in folate-treated mice 
compared to vehicle controls but normalised at 12 weeks. Both urinary ADMA 
and SDMA were reduced in response to folate at 2 and 12 weeks (p<0.05). 
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Whole kidney content of all MAs increased by 1.5 to 2-fold at 2 days 
and 2 weeks (p<0.05-0.001) and fell towards baseline at 12 weeks, at which 
point the only MA being significantly elevated was ADMA (approximately 25%; 
p<0.05). 
 
Figure 5. NOx concentrations in whole kidney and urine in folate nephropathy 
NOx (nitrates and nitrites; stable end-products of NO activity) were measured by ozone 
chemiluminescence. (A) Kidney tissue NOx was unchanged at 2 days but rose significantly at 
2 weeks, 0.006 vs 0.02 AU (0.0006-0.01 and 0.009-0.03); p<0.05. (B) Urinary NOx initially fell 
at 2 weeks but was increased at 12 weeks; 2 weeks 515 vs 204 AU (416-615 and 134-273); 
p<0.001.12 weeks 282 vs 800 AU (241-323 and 387-1213); p<0.05. Two-way ANOVA with 
Bonferroni’s post test. n=5 (vehicle), n=8 (folate). *p<0.05, **p<0.01, ***p<0.001. (NOTE: The 
measurement of urinary NOx is not necessarily an accurate determination of renal NOS 
activity, particularly in the context of a nitrate-containing diet). 
 
 
2.3.4 Acute inflammatory cytokines 
Pro-inflammatory and pro-fibrotic cytokine mRNA transcription was up-
regulated in whole kidney lysates with specific patterns over the three time-
points (Figure 6). The most acute responses were exhibited by ET-1 and IL6, 
with transcription peaks at 2 days (5-fold and 25-fold respectively; p<0.001) 
before falling towards baseline at 2 and 12 weeks. TNFα mRNA transcription 
was delayed in comparison, with no change at 2 days and a 7-fold peak at 2 
weeks (p<0.001) with a reduced but significant elevation persisting at 12 
weeks (p<0.01). Housekeeper Pol2a transcription did not significantly change 
at any time point.   
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2.3.5 Pro-fibrotic cytokines 
Pro-fibrotic cytokines; TGFβ and Col1 2α were up-regulated acutely at 2 days 
but peaked at 2 weeks (3- and 12-fold respectively) and mRNA transcription 
remained significantly elevated at 12 weeks (Figure 6D-E). 
 
 
 
Figure 6. Whole kidney tissue mRNA transcription of pro-inflammatory (A-C) and pro-
fibrotic (D, E) cytokines in folate nephropathy 
mRNA transcription measured by RT-qPCR. Vehicle vs folate: (A) ET-1 (endothelin-1); 2 
days 0.5 vs 4.6 AU (95% CIs -0.09-1.1 and 3.3-5.9); p<0.001. 2 weeks 0.4 vs 2 AU (0.3-0.5 
and 0.8-3.2); p<0.05. 12 weeks 0.4 vs 0.9 AU (0.3-0.5 and 0.7-1.1); p<0.001; (B) IL6 
(interleukin-6); 2 days 0.8 vs 20 AU (-0.7-2.4 and 8.9-31.8); p<0.001. 2 weeks 0.4 vs 3.2 AU 
(-0.02-08 and 1.6-4.8); p<0.01. 12 weeks 0.2 vs 3.2 AU (0.1-0.4 and -1.8-8.2); p>0.05. (C) 
TNFα (tumour necrosis factor-α); 2 weeks 0.3 vs 2.1 AU (0.1-0.4 and 1.3-2.9); p<0.001. 12 
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weeks 0.7 vs 1.6 AU (0.4-0.9 and 0.9-2.3); p<0.01. (D) TGFβ (transforming growth factor-β); 
2 weeks 0.7 vs 2.2 AU (0.5-0.9 and 1.4-3.0); p<0.01. 12 weeks 0.4 vs 0.8 AU (0.3-0.6 and 
0.6-1.0); p<0.05. (E) Col12α (Collagen1 subunit 2α); 2 days 0.4 vs 1.2 AU (-0.3-1.1 and 0.7-
1.6); p<0.05. 2 weeks 0.2 vs 2.4 AU (0.1-0.2 and 1.1-3.7); p<0.01. 12 weeks 0.1 vs 0.6 AU 
(0.08-0.1 and 0.3-0.9); p<0.01. (F) Housekeeper Pol2a transcription did not change. Two-way 
ANOVA with Bonferroni’s post test. n=5 (vehicle), n=8 (folate).  *p<0.05, **p<0.01, 
***p<0.001. 
 
2.3.6 Histological features 
Severe tubulointerstitial disease was evident in kidney sections from folate-
treated mice (Figure 7). At 2 days; tubular dilatation and epithelial flattening, 
luminal casts; tubular atrophy. At 2 weeks; interstitial inflammatory cell 
infiltrates and 12 weeks; tubular atrophy and areas of extra-cellular matrix 
deposition. Vehicle-treated mice displayed normal histological appearances at 
all time points. 
2.3.7 Renal fibrosis (collagen deposition) 
Collagen deposition quantified by picrosirius red immunostaining was 
significantly elevated in animals treated with folate at 2 and 12 weeks (vehicle 
vs folate: 2 weeks, 4 vs 5.7%, p<0.01; 12 weeks, 2.7 vs 6.4%, p<0.001). 
Figure 8). 
 
Page 47 of 60
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
Figure 7. Representative histological features of folate nephropathy  
A, C and E: vehicle controls displayed normal histological appearances; dense with tubules, 
their lumina barely visible.  B, D and F: folate-treated mice at 2 days, 2 and 12 weeks 
respectively. Gross and diffuse tubular dilatation (td) with some luminal casts (lc) was visible 
at 2 days (B). Some resolution of tubular dilatation was apparent at 2 weeks (D), but with 
added presence of interstitial inflammatory cells (inc) (darker nuclei). By 12 weeks (F), some 
earlier features remained but with marked expansion of extra-cellular matrix (ecm), tubular 
atrophy and some glomerulosclerosis seen lower left quadrant. Representative of n=5 (PBS 
vehicle) and n=8 (folate). PAS stain, x20 magnification. Bars = 50 µm.  
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Figure 8. Renal collagen deposition in folate nephropathy 
Representational images of kidney sections from mice treated with (i-ii) Vehicle and (iii-iv) 
Folate. Stained with picrosirius red and viewed through circularly polarised light. A detailed 
description of this method, developed with the assistance of Dr Dorman (MRC CSC, London), 
is reported in the Methods section. Section area defined through texture thresholding (i and 
iii). Capsular collagen was excluded from the analysis by automated circumferential reduction 
of the analysed perimeter (double lines). Background is subtracted to measure percentage 
collagen per total section area (ii and iv). (G) Percentage collagen deposition is significantly 
elevated at 2 and 12 weeks. 2 weeks (vehicle vs folate); 4.0 vs 5.7% (95% CIs 3.0-5.1 and 
4.4-6.9); p<0.01. 12 weeks; 2.7 vs 6.4% (1.7-3.7 and 5.2-7.6); p<0.001. Two-way ANOVA 
with Bonferroni’s post test. n=5 (vehicle), n=8 (folate). *p<0.05, **p<0.01, ***p<0.001. 
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3 CHARACTERISATION OF THE UNILATERAL URETERIC OBSTRUCTION (UUO) 
NEPHROPATHY MODEL 
3.1 Introduction 
Unilateral ureteric obstruction in experimental animals has been used to 
examine mechanisms of human kidney disease for over fifty years and has 
become a well-established rodent model of renal fibrosis. 5 Within hours of 
ureteric ligation, renal blood flow and glomerular filtration rate decline rapidly 
as progressive hydronephrosis develops to cause tubular cell death, 
inflammatory cell infiltration and significant fibrosis within seven days. 6   
Advantages over other models include rapid and reproducible 
development of disease, the absence of an exogenous nephrotoxin with 
potential confounding effects and the use of the contralateral kidney as a 
control (although compensatory change in response to UUO has to be 
considered). Disadvantages include the additional skill and resource required 
for recovery surgery, the absence of a systemic “uraemic state” to model 
human CKD, and reduced or absent biomarkers of disease severity such as 
serum creatinine or proteinuria from the affected kidney. 
Prior to adopting this method, it was important to characterize the UUO 
model to understand the natural course of injury and assess the quality of 
data obtained from this model. 
3.2 Study design and methods 
Thirty, 10-week old female WT C57BL6 littermate mice purchased from 
Charles River Ltd (Kent, UK) were randomly assigned to either unilateral 
ureteric obstruction or sham surgery (4 and 6 mice in each treatment arm 
respectively). Under isoflurane inhalation anaesthesia, mice were shaved, 
draped and positioned on a heat mat. In the supine position, a left flank 
incision exposed the left ureter and was ligated twice with 4-0 nylon sutures 
and transected. Following suture closure, animals received intramuscular 
diclofenac analgesia (Vetagesic) and recovered in heated chambers. No 
surgical complications or premature deaths were experienced in this study. 
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Mice were sacrificed by cervical dislocation followed by organ harvesting at 
three time points; 1, 2 and 3 weeks. 
3.3 Results 
3.3.1 Kidney appearance 
Significant hydronephrosis featuring marked pale discoloration of thinning of 
the renal parenchyma was evident at all time points from week 1 into week 3, 
(Figure 9). 
 !
Figure 9. Typical appearance of kidneys in the UUO nephropathy model 
Pictured are those harvested at 2 weeks following UUO. The left obstructed kidney is grossly 
dilated following complete obstruction.  
 
 
3.3.2 Serum creatinine 
Serum creatinine has previously been reported to be unaffected in the UUO 
model, 7 however serum creatinine was raised in this study at each time-point, 
but significantly at 3 weeks by 70% in UUO-treated mice (p<0.001; Figure 10). 
This reflects an inability of the contralateral kidney to adequately compensate. 
Reasons for this are unclear. Mice were not exposed to additional systemic or 
renal compromise and it may reflect differences between strains (C57 strain 
used here) or even different genetic ancestry within strains.  
 
 
 
 
Right 
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Left 
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Figure 10. Serum creatinine following UUO 
Serum creatinine quantified by LC-MS/MS. Sham versus UUO-treated; 7.3 vs 12.3 µM; 
p<0.001; (95% CI 2.2-7.7).Two-way ANOVA with Bonferroni’s post test. n=4 (sham), n=6 
(UUO).  ***p<0.001!
3.3.3 Physiological parameters 
At 1 week following surgery, body weight fell 2-fold in UUO mice versus sham 
controls (Figure 11A). At 2 weeks, body weights recovered towards pre-
surgical baselines although a trend for lower weight remained in UUO-treated 
mice. No significant differences in urine output between sham- and UUO-
treated mice were observed although a trend for higher values in UUO mice is 
consistent with adaptive hyperfiltration in the contralateral kidney (Figure 
11B). No significant systemic blood pressure differences were observed at 
any time point (Figure 11C), consistent with previous reports of UUO being a 
normotensive model of nephropathy. 7 
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Figure 11. Body weight change, urine output and systolic blood pressure following 
UUO 
(A) Percentage body weight reduction from pre-surgical baseline at 1 and 2 weeks following 
UUO. UUO-treated mice had a two-fold higher weight loss at 1 week than sham-operated 
controls (Sham versus UUO-treated; 3.99 vs 7.79%; p<0.05 (95% CI 0.27-7.3). No significant 
differences in urine output (B) or systolic BP (C) at any time point. Two-way ANOVA with 
Bonferroni’s post test. n=4 (sham), n=6 (UUO).  *p<0.05!
 
 
3.3.4 Profibrotic and inflammatory cytokines 
Expression of profibrotic (TGFβ, Col1α2 and ET-1; 17 - 21-fold) and pro-
inflammatory (IL-6 and TNFα) genes was significantly increased in kidney 
tissues from UUO-treated mice when compared to sham-treated controls 
(Figure 12). Peaks in gene expression occurred at 2 – 3 week time-points with 
the exception of ET-1 (1 week). 
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Figure 12. Kidney tissue profibrotic and inflammatory gene expression following UUO 
mRNA transcription measured by RT-qPCR. Col12α (Collagen1 subunit 2α); TGFβ 
(transforming growth factor-β ET-1 (endothelin-1); IL6 (interleukin-6); TNFα (tumour necrosis 
factor-α); Two-way ANOVA with Bonferroni’s post test. n=4 (sham), n=6 (UUO). **p<0.01, 
***p<0.001 !!
 
 
 
 
 
1 w
ee
k
2 w
ee
ks
3 w
ee
ks
0.0
0.5
1.0
1.5
Sham
UUO
** ***
***
C
ol
la
ge
n 
I-!
2 
m
R
N
A
 (A
U
, c
or
re
ct
ed
 fo
r P
ol2
a)
1 w
ee
k
2 w
ee
ks
3 w
ee
ks
0.0
0.5
1.0
1.5
2.0
Sham
UUO**
ET
-1
 m
R
N
A
(A
U
, c
or
re
ct
ed
 fo
r P
ol2
a)
1 w
ee
k
2 w
ee
ks
3 w
ee
ks
0.0
0.5
1.0
1.5
Sham
UUO
**
***
***
TN
F!
 m
R
N
A
(A
U
, c
or
re
ct
ed
 fo
r P
ol
2a
)
1 w
ee
k
2 w
ee
ks
3 w
ee
ks
0.0
0.5
1.0
1.5
Sham
UUO
*** *** ***
TG
F"
 m
R
N
A
(A
U
, c
or
re
ct
ed
 fo
r P
ol2
a)
1 w
ee
k
2 w
ee
ks
3 w
ee
ks
0.0
0.5
1.0
1.5
2.0
Sham
UUO
**
IL
6 
m
R
N
A
(A
U
, c
or
re
ct
ed
 fo
r P
ol
2a
)
A B 
C D 
E 
Page 54 of 60
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3.3.5 Methylarginine-metabolising enzymes (MAMEs) 
Expression of methylarginine-metabolising enzyme (MAMEs; DDAH1, DDAH2 
and AGXT2) genes in obstructed kidney tissue was significantly altered in the 
UUO model (Figure 13). DDAH1 (1 week 2-fold; 2 weeks 7-fold; 3 weeks 15-
fold) and AGXT2 (1 week 2-fold; 2 weeks 6-fold; 3 weeks 25-fold) gene 
expression was progressively reduced, whilst DDAH2 expression was 
elevated 2 – 3-fold at each time-point. 
These altered expression profiles reflect their cell-type specific 
expression. DDAH1 and AGXT2 in the kidney are known to be almost 
exclusively expressed within the tubular epithelium, 8 whilst DDAH2 is known 
to be induced within the macrophage by an inflammatory stimulus (our own 
findings; paper in submission). The UUO model causes widespread tubular 
damage and hence a large proportion of DDAH1/AGXT2-expressing cells are 
lost. How DDAH1 expression from surviving tubular cells affects progressive 
fibrosis forms the basis for this body of work. 
Figure 13. Kidney tissue methylarginine-metabolising enzyme (MAME) expression 
following UUO  
mRNA transcription in kidney tissue measured by RT-qPCR. Two-way ANOVA with 
Bonferroni’s post test. n=4 (sham), n=6 (UUO). *p<0.05, **p<0.01, ***p<0.001 
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3.3.6 Methylarginines 
Asymmetric methylarginines (MAs), L-NMMA and ADMA, are metabolised by 
DDAH whilst SDMA is not. AGXT2 can metabolise all three through 
deamination. Few significant alterations in MAs were detected in the serum, 
kidneys and urine in the UUO model (Figure 14). All three MAs are known to 
rise in the serum or plasma in renal dysfunction8 - a pattern reflected in this 
study. As yet, very little is understood about the role of MAs, MAMES and NO 
at a cell-type specific level in kidney function decline. 
Figure 14. Methylarginine profiles following UUO 
MAs measured by LC/MSMS. Two-way ANOVA with Bonferroni’s post test. n=4 (sham), n=6 
(UUO).  *p<0.05, **p<0.01. 
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3.3.7 Nitric oxide concentrations 
Evidence of nitric oxide activity assessed by quantification of stable end 
products (nitrite and nitrate; NOx). Plasma and urine NOx was not significantly 
altered following UUO at any time point (Figure 15A-B). Obstructed kidney 
tissue NOx was elevated at 2 weeks but only significant at 3 weeks (2-fold; 
p<0.05; Figure 15C), reflecting induced inflammation and increased NO 
production from immune cells. Interestingly, tissue from the contralateral 
kidney expressed a consistent pattern for reduced NOx, suggesting that part 
of the adaptive change exhibited by the single functioning kidney involves 
suppression of NO (Figure 15D). 
 
 
Figure 15. Nitric oxide (NO) activity following UUO 
NOx (nitrates and nitrites; stable end-products of NO activity) measured by ozone 
chemiluminescence. (A) Two-way ANOVA with Bonferroni’s post test. n=4 (sham), n=6 
(UUO). *p<0.05. (NOTE: The measurement of urinary NOx is not necessarily an accurate 
determination of renal NOS activity, particularly in the context of a nitrate-containing diet). 
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3.3.8 Histology  
Severe tubulointerstitial disease was evident in kidney sections from 
obstructed kidneys. At each time-point, gross tubular dilatation and epithelial 
flattening was present with luminal casts (Figure 16).  
 
Figure 16. Renal histology following UUO 
Tissue from sham operated displayed normal histological appearances; dense tubules, their 
lumina barely visible. In obstructed kidneys; gross, diffuse tubular dilatation (td) with some 
luminal casts (lc) evident at all time-points. Some resolution of tubular dilatation was apparent 
at 3 weeks with increased presence of interstitial inflammatory cells (inc) (darker nuclei) and 
marked expansion of extra-cellular matrix (ecm). Severe parenchymal thinning at 3 weeks 
allowing visualisation of the whole thickness in one frame (bottom-right image; pelvis and 
periphery labelled). Representative of n=4 (sham) and n=6 (UUO). PAS stain, x20 
magnification. Bars = 50 µm.  !
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By 2 into 3-week time-points, tubular atrophy occurred with progressive 
interstitial inflammatory cell infiltration and areas of extra-cellular matrix 
deposition. At 3 weeks, marked thinning of the entire renal parenchyma 
(cortex and medulla) was evident with renal pelvis dilatation and further 
distortion of normal architecture (Figures 16 and 17). Sham-operated mice 
displayed normal histological appearances at all time points. 
3.3.9 Renal fibrosis and loss of parenchyma  
Progressive thinning of the renal parenchyma was evident throughout the 
time-course of UUO (Figure 17). Complete ureteric obstruction caused 
significant loss of whole kidney histological section surface area compared to 
sham-operated controls (55% reduction at 3 weeks; p<0.001; Figure 17A). 
Figure 17. Renal fibrosis and parenchymal loss following UUO 
Representational images of left kidney sections from mice following with sham or UUO 
surgery. Stained with picrosirius red and viewed through circularly polarised light. A detailed 
description of this method is reported in the Methods section. Section area defined through 
texture thresholding. Capsular collagen was excluded from the analysis by automated 
1 
w
ee
k 
2 
w
ee
ks
 
3 
w
ee
ks
 
Sham UUO 
Page 59 of 60
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
circumferential reduction of the analysed perimeter (double lines). Background is subtracted 
to measure percentage collagen per total section area (graphical representation; Figure 18A). 
Grossly distorted section morphology with dilated renal pelvis and parenchymal thinning 
evident at 2 and 3 week time-points. 
 ! Significant renal fibrosis or collagen deposition was evident in 
obstructed kidneys (12%; p<0.001; Figure 18B). 
!
Figure 18. Reduced renal parenchyma and fibrosis. 
Kidney section area assessed by reduction in pixel coverage in stitched whole kidney images 
as seen in Figure 13. Percentage collagen deposition quantified across whole kidney sections 
stained with picrosirius red and automated Image J software analysis. Two-way ANOVA with 
Bonferroni’s post test. n=4 (sham), n=6 (UUO). *p<0.05, **p<0.01, ***p<0.001. !
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